In re NorthShore University HealthSystem Antitrust Litig., No.: 1:07-cv-04446 (N.D. Ill.)
After a multi-year battle, Miller Law is pleased to announce the settlement of this class action lawsuit. The case concerns Defendant’s hospital merger in January 2000. Plaintiff Class alleges that the Defendant, a hospital network located in the Northern Suburbs of Chicago, abused monopoly power which resulted in Plaintiff Class paying more than they otherwise […]
In re Zetia (Ezetimibe) Antitrust Litigation, Case No. 2:18-md-2836 (E.D. Va.)
We are pleased to announce the final approval of the settlement of this class action lawsuit. The case involved alleged pay-for-delay antitrust violations by various defendants. Miller Law, as court-appointed co-lead class counsel, represented a class of end-payor plaintiffs who alleged defendants unlawfully delayed the availability of less-expensive generic versions of Zetia and caused […]
In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litig., MDL No. 2445 (E.D. Pa.)
Miller Law is pleased to announce that the District Court presiding over this matter has preliminarily approved the class action settlement between the end-payor plaintiff class and defendant Indivior f/k/a Reckitt Benckiser Pharmaceuticals. Under the terms of the settlement, and among other things, Indivior has agreed to pay the class $30,000,000.00. A copy of the preliminary approval […]
In re Zetia (Ezetimibe) Antitrust Litigation, Case No. 2:18-md-2836 (E.D. Va.)
We are excited to announce the settlement of this class action lawsuit. The case involved alleged pay-for-delay antitrust violations by various defendants. Plaintiffs alleged that Defendants unlawfully delayed the availability of allegedly less-expensive generic versions of Zetia and that Defendants’ alleged conduct caused third-party payors to pay too much for branded and generic Zetia […]
In re Namenda Indirect Purchaser Antitrust Litigation, No. 15-cv-6549 (S.D.N.Y.)
We are pleased to announce the settlement of this class action lawsuit. The case involved alleged pay-for-delay antitrust violations by various defendants. The Brand Defendants have agreed to contribute $54,400,000.00 to the settlement fund, and the Generic Defendants have agreed to contribute $2,038,000.00. The settlement encompasses all class members. A final approval hearing is scheduled […]
Smith v. FirstEnergy Corp., et al., Case No. 2:20-cv-3755 (S.D. Ohio)
Miller Law attorneys and co-lead class counsel have settled the class action lawsuit, Smith v. FirstEnergy Corp. (Case No. 2:20-cv-3755). The case involved allegations against Defendants including FirstEnergy, Ohio Edison, and Energy Harbor for racketeering schemes impacting electricity charges. The total settlement involves FirstEnergy and Energy Harbor collectively contributing $49,000,000.00 to the settlement class. A […]
In Re Loestrin Antitrust Litig., MDL No. 2472 (D. R.I.)
Miller Law is pleased to announce that settlements have been reached with certain defendants in this class action involving oral contraceptives Loestrin 24 Fe and Minastrin 24 FE. The settling defendants have agreed to pay a total of $63.5 million into a settlement fund for the settlement classes. For additional information concerning the settlements, please […]
In re Liquid Aluminum Sulfate Antitrust Litig., Case No. 16-md-02687 (D. NJ)
Miller Law attorneys are pleased to announce that they, along with co-lead class counsel, have reached a settlement of this class action lawsuit with the defendants on behalf of the plaintiff class. This lawsuit is about the price of liquid aluminum sulfate and whether its manufacturers conspired to fix, stabilize, or maintain its price […]
In re Solodyn Antitrust Litig., 1:14-md-02503 (D. Mass.)
A proposed $23 million settlement has been reached in this class action lawsuit involving the antibiotic drug Solodyn®. The lawsuit claims that Medicis Pharmaceutical Corp., Impax Laboratories, Inc., Lupin Limited, Lupin Pharmaceuticals Inc., and Sandoz Inc. (the “Defendants”) violated state competition (i.e. antitrust and consumer protection) and unjust enrichment laws by agreeing not to compete […]
In re Aggrenox Antitrust Litig., MDL No. 02516 (D. Ct.)
A proposed $54 million settlement has been reached in this class action lawsuit regarding the prescription drug Aggrenox® (aspirin/extended-release dipyridamole). The lawsuit claims that Defendants Boehringer Ingelheim and Teva Pharmaceutical hurt competition and violated state laws by delaying the availability of less-expensive generic versions of Aggrenox®. Click here for more information.